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Abstract: The Centre for the AIDS Program of Research in South
Africa 004 trial demonstrated reduction of sexual HIV-1 acquisition
in women using a vaginal microbicide containing tenofovir. A better
understanding of the consequences of antiretroviral-containing
microbicides for immune responses in individuals with intercurrent
HIV-1 infection is needed for future trials combining the use of
microbicides with HIV-1 vaccines. Investigation of immune
responses in women who acquired HIV-1 although using tenofovir
gel showed significantly higher (P = 0.01) Gag-specific IFNg+
CD4+ T-cell responses. The use of tenofovir-containing gel around
the time of infection can modulate HIV-1 immunity, and these
immunological changes need to be considered in future trials com-
bining vaccines and microbicides.
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INTRODUCTION
A recent randomized controlled trial undertaken by the
Centre for the AIDS Program of Research in South Africa
(CAPRISA) reported that a vaginal microbicide gel con-
taining 1% tenofovir reduced the risk of HIV-1 infection in
women by 39%.1 Although confirmation of these findings in
additional studies are needed and similar studies are cur-
rently underway, these results will have significant implica-
tion for the design of future prevention trials, including
vaccine trials in which both vaccinees and placebo recipients
might receive prophylactic antiretroviral drugs in gel or oral
formulation.2 A better understanding of the consequences of
antiretroviral-containing microbicides for immune responses
in individuals with intercurrent HIV-1 infection is therefore
critical to take these immunological changes into consider-
ation in the design of future trials combining the use of
microbicides with HIV-1 vaccines.2 In the present study,
we investigated innate and adaptive immune responses dur-
ing primary HIV-1 infection in women who acquired HIV-1




Cryopreserved peripheral blood mononuclear cell
(PBMCs) were collected from sexually active HIV-1 clade
C–infected 18-year-old to 40-year-old women in urban
and rural KwaZulu-Natal, South Africa, enrolled in CAP-
RISA 004.1 The eligibility and exclusion criteria for the par-
ent trial have been previously reported.1 Participants who
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acquired HIV stopped using study gel on confirmation of HIV
infection, as per the trial protocol.1 From the total
of 98 intercurrent HIV infections that occurred, 36 randomly
selected HIV-1–infected female adults exposed either to
tenofovir gel (n = 17) or placebo (n = 19) were selected
for this substudy. The study was approved by the Univer-
sity of KwaZulu-Natal and Massachusetts General Hospital
Biomedical Research Ethics Committee, Family Health In-
ternational Protection of Human Subjects Committee, and
the South African Medicines Control Council with each
subject giving informed consent for participation.
Characterization of Phenotype and Function
of Innate and Adaptive Immune Cells Using
Multiparameter Flow Cytometry
The phenotypic characteristics of natural killer (NK)
cells and myeloid dendritic cells (mDCs) were assessed by
multiparameter flow cytometry using cyropreserved PBMC
collected within 3 months of HIV-1 infection. After gating on
lineage negative (CD3neg, CD19neg, CD56neg) lympho-
cytes, anti-CD11c was used to identify mDCs, as described.3,4
Antibodies directed against Human Leukocyte Antigen
(HLA)-DR, CD83, and CD86 were used to study the activa-
tion and maturation stage of mDCs directly ex-vivo. NK cells
were defined as CD3negCD56/CD16+ cells, and antibodies
directed against HLA-DR, CD38, and CD69 were used to
study the activation status of NK cells, as described.5
Intracellular measurement of interferon gamma (IFN-g),
tumor necrosis factor alpha (TNF-a), and interleukin 2 (IL-2)
production by CD4+ and CD8+ T cells was undertaken as
described.6,7 Cryopreserved PBMCs were stimulated for
6 hours at 37°C; 5% CO2 with Gag and Nef peptide pools
spanning the HIV-1 clade C consensus sequence (final concen-
tration 2mg/ml per peptide) in the presence of brefeldin A.
Negative controls with PBMCs and media alone and positive
controls stimulated with phytohemaggultinin were included in
the assays. Between 500,000–1,000,000 events were acquired
on a LSRII flow cytometer, and data analysis was performed
using FlowJo version 8.8.2 (TreeStar, Inc). Boolean gating was
used to create a full array of the 8 possible response patterns
when testing 3 functions, and data were further analyzed using
SPICE 5 and PESTLE software programs (kindly provided by
Drs Roederer and Nozzi, National Institute of Allergy and
Infectious Diseases, National Institutes of Health).
Statistical Analyses
Statistical analyses and graphical presentation was done
using Graphpad Prism 5 (Graphpad). Results are given as
averages with standard deviations. Paired 2-tailed Student t tests
were used to test statistical significance. Differences after com-
parisons were considered statistically significant if P , 0.05.
RESULTS
Characteristics of Study Subjects
Cryopreserved PBMCs collected from 36 sexually
active HIV-1–infected women in urban and rural KwaZulu-
Natal enrolled into the CAPRISA 004 trial1 were randomly
selected and studied. Investigators were blinded regarding the
study group for the immunological analysis. Seventeen of
these women were part of the tenofovir gel arm and 19 of
the placebo arm. The demographic, immunological, and viro-
logical characteristics of the study cohort are presented in
Table 1. Women in the 2 arms did not differ in the days since
infection, and HIV-1 viral loads and CD4+ T-cell counts at
presentation or analysis, and did also not differ in the distri-
bution of low, intermediate, and high adherers.
Lack of Differences in Innate Immune Cells
Between the Study Arms at 3 Months
Post Infection
We initially examined the frequencies and activation
status of NK cells and mDCs between women in the tenofovir
or placebo arms. The average frequencies of NK cells did not
differ between the 2 arms (average NK cells 4.7% ± 3.8% vs.
5.5% ± 4.6%). Furthermore, the average percentage of
NK cells expressing HLA-DR (12% ± 6.3% vs. 12.9% ±
9.2%), CD38 (68.9% ± 25.3% vs. 67.1% ± 28.6%) or
CD69 (10.3% ± 10.9% vs. 10.7% ± 7.1%) did not differ
between the women who received tenofovir compared with
those who received placebo (P . 0.05 for all comparisons).
Similarly, the average percentage of mDCs (5.7% ± 3.2% vs.
5.9% ± 1.9%) and their activation status (HLA-DR: 19.8% ±
19.5% vs. 17.5% ± 11.3%; CD83: 6.8% ± 9.5% vs. 6.7% ±
4.2%, and CD86: 19.3% ± 21.4% vs. 11.5% ± 11.7%; p .
0.05 for all comparisons) did not differ between tenofovir and
placebo gel recipients. Taken together, these data demonstrate
that frequencies and activation status of cells of the innate
immune system were not significantly impacted by the use
of tenofovir gel in women with breakthrough HIV-1 infection
approximately 3 months after infection.
Preservation of HIV-1–Specific IFNg CD4+
T Cells During Primary Infection
Previous studies have shown that HIV-1 Gag and Nef
are targeted by HIV-1–specific T cells during primary infec-
tion, and that virus-specific CD4+ T-cell responses are rapidly
lost after infections.8 We compared HIV-1 clade C Gag-
specific and Nef-specific CD4+ and CD8+ T-cell activity
TABLE 1. Characteristics of Study Subjects
Tenofovir Placebo P
n 17 19 —
Age 24 (19–37) 23 (19–31) 0.69
Days post infection 85 (20–345) 64 (15–481) 0.30
Initial CD4+ T-cell count 454 (182–955) 556 (240–1036) 0.17
CD4+ T-cell count
post infection
464 (197–955) 510 (240–1036) 0.11
Initial viral log (log) 4.66 (2.60–6.53) 4.42 (2.60–5.85) 0.72
Viral load post
infection (log)
4.96 (2.60–5.86) 4.51 (2.60–5.51) 0.58
Average and range is shown.
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between women who received tenofovir gel or placebo recip-
ients. As shown in Figure 1, Gag-specific IFN-g+ CD4+ T-
cell responses were significantly higher in the women in the
tenofovir gel arm compared with placebo (P = 0.01). No cor-
relation was observed between days postinfection and Gag-
specific IFN-g+ CD4+ T-cell responses (R = −0.2; P = 0.3).
HIV-1 Nef-specific CD4+ T-cell responses also trended to be
higher in women in the tenofovir gel arm compared with
placebo recipients (P = 0.08, Fig. 1). No significant differ-
ences were observed in the percentage of Gag-specific and
Nef-specific CD4+ T-cells producing TNF-a or IL-2 between
the 2 groups (data not shown).
Gag-specific and Nef-specific IFN-g+ CD8+ T-cell
responses were also higher in the tenofovir arm compared
with placebo though those differences did not reach statis-
tical significance (Gag: average 1.1% IFN-g+ CD8+ T
cells ± 1.0% in tenofovir arm vs. 0.7% ± 0.7% in placebo,
P = 0.33; Nef: average 1.1% IFN-g+ CD4+ T cells ±
1.4% in tenofovir arm vs. 0.35% ± 0.5% in placebo, P
= 0.35). Furthermore, Gag and Nef-specific CD8+ T cells
IL-2 and TNF-a production did not differ significantly
between the 2 groups (data not shown). We also assessed
the polyfunctionality of the CD4+ and CD8+ T cells by
the simultaneous quantification of three functions (IL-2,
IFN-g, and TNF-a production) in response to Gag and
Nef stimulation and observed no significant differences
in the polyfunctionality of the CD4+ and CD8+ T cells
in the tenofovir arm compared with placebo (P . 0.05).
Overall, a vast majority of HIV-1–specific T cells were
monofunctional (.90%) in both the tenofovir gel and pla-
cebo group. Taken together, these data demonstrate that
the HIV-1–specific CD8+ T-cell responses in women with
breakthrough infection during tenofovir microbicide use
did not significantly differ from those that used placebo,
but that Gag-specific IFNg+ CD4+ T cells responses were
significantly higher in HIV-1–infected women randomized
to the tenofovir gel arm.
DISCUSSION
The use of a tenofovir-containing vaginal microbicide
gel for the prevention of HIV-1 infection in sexually active,
HIV-1–uninfected adult women in KwaZulu-Natal, South Africa,
showed a significant reduction of HIV-1 infection rates by
39% in the primary intent-to-treat analysis.1 Here, we exam-
ined the innate and adaptive immune responses in women
with breakthrough HIV-1 infection that either used tenofovir
microbicide gel or were part of the placebo arm. The frequen-
cies and activation status of principal effector cells of the
innate immune response, including NK cells and mDCs,
assessed within 3 months of HIV-1 infection were not affected
by the use of the tenofovir gel. Previous studies have demon-
strated a significant expansion of NK cells in infected
individuals during the early phase of HIV-1 infection
and a subsequent contraction of NK cell and mDC popula-
tions.9–11 We can therefore not exclude that NK cell and
mDC frequencies in the initial 3 months of infection might
have been affected by the use of the tenofovir gel, and
that these changes in innate effector cells might have sub-
sequently contributed to the observed functional differences
in HIV-1–specific CD4+ T cells.12
HIV-1–specific T cells are considered critical for the
control of HIV-1 replication and disease progression.8,13–15
Although HIV-1–specific CD8+ T-cell responses to both
Gag and Nef peptides did not significantly differ between
the groups, HIV-1 Gag-specific IFN-g+ CD4+ T-cell
responses were significantly higher in women in the
tenofovir gel arm compared with the placebo arm. HIV-
1–specific CD4 + T cell responses are rapidly lost after
acute infection in the presence of continuing HIV-1 repli-
cation, and this is in contrast to HIV-1–specific CD8+
T-cell frequencies which tend to increase over at least the
first year of HIV-1 infection with continues exposure to
antigen.16–20 Previous studies have shown that CD4+ T cells
and in particular gut-associated CD4+ T cells are severely
depleted within the first few days/weeks of infection21 and
that HIV-1 preferentially infects HIV-1–specific CD4+ T
cells.22 The presence of an antiretroviral agent, such
as tenofovir, during this crucial period might protect CD4
+ T cells from deletion, allowing for a preservation of HIV-
1-specific IFN-g CD4+ T cells. The observation that
women receiving tenofovir gel maintained higher Gag-spe-
cific CD4+ T-cell responses despite the reported lack of
differences in viral load set-point between tenofovir gel
and placebo recipients1 was however unexpected, and the
long-term clinical benefit of this preservation, and its con-
sequences for HIV-1-specific immune function, will require
further investigation.
FIGURE 1. Higher HIV-1 Gag-specific
and Nef-specific CD4+ T-cell respon-
ses in tenofovir recipients. The dot
plot represents the median % IFNg+
CD4+ T cells in response to HIV-1 Gag
(left panel) and Nef (right panel) in
women enrolled in the tenofovir arm
(n = 17) compared with women who
received placebo (n = 19).
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Taken together, our studies in a subset of women who
experienced breakthrough HIV-1 infection despite randomi-
zation to tenofovir gel usage demonstrate no significant alter-
ation in the frequencies and activation status of key innate
immune cells and HIV-1–specific CD8+ T-cell responses
3 months after infection. However, tenofovir gel applied vag-
inally around the time of HIV-1 transmission might protect
HIV-1–specific CD4+ T-cell responses in infected individu-
als. This study demonstrates for the first time that the use of
vaginal microbicides containing antiretroviral drugs can mod-
ulate HIV-1–specific immunity in individuals with break-
through infection. These consequences of microbicide use
for immune responses in individuals that acquire HIV-1 have
to be considered in the design of future trials that will com-
bine microbicides with HIV-1 vaccines.
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